leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical says current stage of analgesic research program soon to complete, with results currently being compiled and analyzed

The Analgesic Program started in July 2018 in order to expand the use of the University of Queensland's disulfide linker technology to develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation for possible commercialization

PreveCeutical Medical Inc. -
PreveCeutical said it will provide results of the Analgesic Program when it has fully analyzed them.

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) has announced that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program is soon to complete, with the results currently being compiled and analyzed.

The Analgesic Program started in July 2018 in order to expand the use of the University of Queensland's disulfide linker technology to develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation for possible commercialization, the company noted.

READ: PreveCeutical advances Dual Gene Therapy Research Program combatting Type 2 diabetes and obesity

PreveCeutical said it will provide results of the Analgesic Program when it has fully analyzed them.

In a statement, PreveCeutical's chair and chief executive officer, Stephen Van Deventer commented: "We are very pleased with the progress of our research and development programs, including the expected completion of the Analgesic Program, which is the third program that we have with UniQuest Pty Limited.

“We believe that potential pain therapies from this Analgesic Program will be very important in addressing the current global opioid crises."

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

The company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

CSE:PREV
Market: CSE
Market Cap: $17.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read